Obiltoxaximab SFL is a medicine used with antibiotic treatment to treat inhalational anthrax, a serious disease caused by the bacteria Bacillus anthracis. ‘Inhalational’ means that the person catches the disease by breathing in spores, which develop into active bacteria in the body and release harmful toxins. The medicine is also used to prevent inhalational anthrax in people who have come into contact with the bacteria spores and when no other appropriate treatment is available. Obiltoxaximab SFL contains the active substance obiltoxaximab. Anthrax is rare, and Obiltoxaximab SFL was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 24 August 2018.
Therapeutic Indication
### Therapeutic indication Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1). Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
J06BB22
ATC Item
xj 06 bb 22
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nyxthracis | N/A | nyxthracis |
EMA Name
Nyxthracis (previously Obiltoxaximab SFL)
Medicine Name
Nyxthracis (previously Obiltoxaximab SFL)
Aliases
N/ANo risk management plan link.
